Climb Bio
CLYM
79 hedge funds and large institutions have $100M invested in Climb Bio in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 18 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 12
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
11% more funds holding
Funds holding: 71 → 79 (+8)
1.35% more ownership
Funds ownership: 81.52% → 82.87% (+1.4%)
64% less capital invested
Capital invested by funds: $278M → $100M (-$178M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.68M |
| 2 |
CF
Cantor Fitzgerald
New York
|
+$2.35M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$1.98M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.68M |
| 5 |
BlackRock
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$4.09M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$3.62M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.12M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.01M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$1.7M |
CLYM Hedge Fund Activity: Q4 2024 in Review
79 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q4 2024, worth a combined $100M — down 64% from $278M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CLYM positions and 18 closed out — a net gain of 8 holders — while 28 added to existing stakes and 12 trimmed.
The largest buyer was Bank of America, adding an estimated $3.68M. The largest seller was Deep Track Capital, cutting an estimated $4.09M.
- 79 institutional investors held Climb Bio (CLYM) as of Q4 2024, up from 71 in Q3 2024.
- Funds reported $100M of Climb Bio stock for Q4 2024, down 64% quarter-over-quarter.
- 26 funds opened new Climb Bio positions in Q4 2024 and 18 closed out, a net change of +8 holders.
- The largest Climb Bio buyer in Q4 2024 was Bank of America, an estimated $3.68M added.
- The largest Climb Bio seller in Q4 2024 was Deep Track Capital, an estimated $4.09M sold.
Based on aggregated 13F filings for Q4 2024.